Poseida Therapeutics (Poseida Therapeutics) Cash-to-Debt : 2.48 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Poseida Therapeutics Cash-to-Debt Definition

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Poseida Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.48.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Poseida Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Poseida Therapeutics's Cash-to-Debt or its related term are showing as below:

PSTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.59 Med: 3.18 Max: 5.21
Current: 2.48

During the past 7 years, Poseida Therapeutics's highest Cash to Debt Ratio was 5.21. The lowest was 1.59. And the median was 3.18.

PSTX's Cash-to-Debt is ranked worse than
64.72% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs PSTX: 2.48

Poseida Therapeutics Cash-to-Debt Historical Data

The historical data trend for Poseida Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Poseida Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

4.30

5.21

3.37

3.18

2.48

Poseida Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															3.18	2.81	2.46	2.77	2.48

Competitive Comparison

For the Biotechnology subindustry, Poseida Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poseida Therapeutics Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Poseida Therapeutics's Cash-to-Debt falls into.

Poseida Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Poseida Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	212.202	/	(5.951	+	79.472)
	=	2.48

Poseida Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	212.202	/	(5.951	+	79.472)
	=	2.48

Poseida Therapeutics (NAS:PSTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Poseida Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Poseida Therapeutics (Poseida Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (NAS:PSTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

2RZ:Germany

Address

9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.poseida.com

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Executives

John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Luke Corning	director	614 DAVIS STREET, EVANSTON IL 60201
Marcea Bland Lloyd	director	9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Cynthia Collins	director	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Rafael Amado	director	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Kristin Yarema	officer: President, Cell Therapy	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Malin Life Sciences Holdings Ltd	10 percent owner	2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
Eric Ostertag	director, 10 percent owner, officer: Chief Executive Officer	C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Kerry D. Ingalls	officer: Chief Operating Officer	C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Brent Warner	officer: President, Gene Therapy	C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Matthew A. Spear	officer: Chief Medical Officer	C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Harry J Leonhardt	officer: GC & Chief Compliance Officer	C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
David Hirsch	director	C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Sean Murphy	director, 10 percent owner	C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703